As of April 2, 2026, Docebo Inc's estimated intrinsic value ranges from $15.03 to $55.43 per share, depending on the valuation methodology applied.
| Valuation Method | Fair Value (USD) | Implied Upside/Downside |
|---|---|---|
| Discounted Cash Flow (10Y) | $47.13 | +93.3% |
| Discounted Cash Flow (5Y) | $34.50 | +41.5% |
| Dividend Discount Model (Multi-Stage) | $29.51 | +21.1% |
| Dividend Discount Model (Stable) | $55.43 | +127.3% |
| Earnings Power Value | $15.03 | -38.4% |
Is Docebo Inc (DCBO.TO) undervalued or overvalued?
With the current market price at $24.38, the stock appears to be significantly undervalued.
Intrinsic value represents the "true" worth of a company based on its fundamentals rather than market sentiment. We've employed multiple methodologies to triangulate Docebo Inc's intrinsic value, including:
The cost of capital is a critical factor in valuation models, representing the required return for investors.
| WACC Component | Low | High |
|---|---|---|
| Long-term bond rate | 3.2% | 3.7% |
| Equity market risk premium | 5.1% | 6.1% |
| Adjusted beta | 0.62 | 0.75 |
| Cost of equity | 6.3% | 8.7% |
| Cost of debt | 5.0% | 5.0% |
| Tax rate | 11.6% | 24.2% |
| Debt/Equity ratio | 0.01 | 0.01 |
| After-tax WACC | 6.3% | 8.7% |
Our DCF model projects cash flows over 5-year and 10-year horizons, with the following key assumptions:
| DCF Model | Fair Value | Enterprise Value | % from Terminal Value |
|---|---|---|---|
| 5-Year Growth | $25 | $643M | 82.5% |
| 10-Year Growth | $34 | $904M | 72.2% |
| 5-Year EBITDA | $16 | $383M | 70.7% |
| 10-Year EBITDA | $22 | $553M | 54.6% |
The DDM values a company based on its expected future dividend payments. We used two approaches:
EPV assesses a company's value based on its current normalized earnings power, assuming no growth.
| EPV Component | Value |
|---|---|
| Normalized Earnings | $17M |
| Discount Rate (WACC) | 8.7% - 6.3% |
| Enterprise Value | $201M - $278M |
| Net Debt | $(71)M |
| Equity Value | $273M - $349M |
| Outstanding Shares | 29M |
| Fair Value | $9 - $12 |
| Selected Fair Value | $15.03 |
| Metric | Value |
|---|---|
| Market Capitalization | $701M |
| Enterprise Value | $602M |
| Trailing P/E | 13.45 |
| Forward P/E | 21.12 |
| Trailing EV/EBITDA | 9.20 |
| Current Dividend Yield | 0.00% |
| Dividend Growth Rate (5Y) | 0.00% |
| Debt-to-Equity Ratio | 0.01 |
To determine the most reliable intrinsic value estimate, we weigh each valuation method based on:
| Valuation Method | Weight | Weighted Value |
|---|---|---|
| Discounted Cash Flow (10Y) | 30% | $14.14 |
| Discounted Cash Flow (5Y) | 25% | $8.62 |
| Dividend Discount Model (Multi-Stage) | 20% | $5.90 |
| Dividend Discount Model (Stable) | 15% | $8.31 |
| Earnings Power Value | 10% | $1.50 |
| Weighted Average | 100% | $38.48 |
Based on our comprehensive valuation analysis, Docebo Inc's intrinsic value is $38.48, which is approximately 57.8% above the current market price of $24.38.
Key investment considerations:
Given these factors, we believe Docebo Inc is currently significantly undervalued with the potential for long-term appreciation based on the company's growth trajectory and financial strength.